IMM2902
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for IMM2902, covering 2023-04-10 to 2024-10-30. Get the full timeline:
Most recent: Clinical Trial Update: IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors [Phase 1]